Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells

Authors

  • Devendra S. Dandekar,

    1. Department of Urology, University of Miami School of Medicine, Miami, FL, USA
    Search for more papers by this author
  • Monica Lopez,

    1. Department of Urology, University of Miami School of Medicine, Miami, FL, USA
    Search for more papers by this author
  • Robert I. Carey,

    1. Department of Urology, University of Miami School of Medicine, Miami, FL, USA
    Search for more papers by this author
  • Bal L. Lokeshwar

    Corresponding author
    1. Department of Urology, University of Miami School of Medicine, Miami, FL, USA
    2. Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL, USA
    3. Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA
    • Department of Urology Research Laboratories, University of Miami School of Medicine, P.O. Box 016960 (M-800), Miami, FL 33101
    Search for more papers by this author
    • Fax: +305-243-6893


Abstract

Many tumors constitutively express high levels of the inducible form of proinflammatory enzyme, cyclooxygenase-2 (COX-2). Increased COX-2 expression is associated with tumor cell resistance to many cytotoxic chemotherapy drugs. Furthermore, increased resistance to cytotoxic antitumor drugs is also known to be dependent on associated stromal cells in many tumors. We investigated whether prostate tumor-associated stromal cells, marrow-derived osteoblasts, affect cytotoxicity of 2 antitumor drugs, COL-3 and docetaxel (TXTR), and whether it is dependent on COX-2 activity. We further examined whether inhibiting the activity of COX-2 negate the stroma-induced decrease in drug sensitivity in tumor cells. COX-2-specific inhibitor celecoxib (CXB) was used to inhibit COX-2 activity and associated alteration in cell death signaling was investigated. Coculturing PC-3ML cells with osteoblasts decreased the cytotoxicity of the tested antitumor drugs and was associated with increased COX-2 activity in PC-3ML cells. A significant decrease in drug-induced PGE2 increase and an increase in cytotoxicity were observed when cells were treated with COL-3 or TXTR combined with CXB. Cytotoxicity of single or combination treatment increased apoptosis, which was associated with caspase-3 and -9 activation, PARP cleavage, increased BAD protein, but decreased protein levels of XIAP and BCL-xL. Oral administration of CXB (40 mg/kg) to mice with PC-3ML tumors for 42 days increased tumor latency, decreased tumor growth and enhanced tumor control with COL-3 or TXTR. Overall, a synergistic enhancement of antitumor activity in combination treatment was observed in vitro and an additive effect in vivo. These observations suggest a potential clinical use of combined dosing of COX-2 inhibitors and cytotoxic drugs at lower, nontoxic dose than currently used to treat advanced prostate cancer. © 2005 Wiley-Liss, Inc.

Ancillary